In-stent restenosis (ISR) is an adverse event of percutaneous coronary intervention (PCI) procedures [1]. Drugeluting stents (DES) have been shown to reduce the incidence of ISR to around 5% in contrast to bare metal stents (BMS), which have a 25% incidence. Patients with ISR may present with recurrence of anginal symptoms or an acute ischemic event and may need further PCI or bypass surgery [2].